HIV-1 integrase inhibitors: An emerging clinical reality

被引：44

作者：

Dayam R. ^{[1
]}

Al-Mawsawi L.Q. ^{[1
]}

Neamati N. ^{[1
,2
]}

机构：

[1] Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA

[2] Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089

来源：

Drugs in R & D | 2007年 / 8卷 / 3期

关键词：

Strand Transfer; Potent Antiviral Activity; Catalytic Core Domain; Optimise Background Therapy; Quinolone Carboxylic Acid;

D O I：

10.2165/00126839-200708030-00003

中图分类号：

学科分类号：

摘要：

From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it has taken 15 years to achieve success in human clinical trials. Currently available antiretroviral drugs set high clinical standards in efficacy and long-term safety for upcoming novel HIV/AIDS therapeutic agents. The results from advanced stages of human clinical trials with IN inhibitors indicate a promising future for these compounds as a novel class of antiretroviral drugs. Success and failure of previously discovered antiretroviral drugs have taught us that there are no magic bullets in eradicating HIV. However, approval of drugs selectively targeting IN has long been awaited. There is once again a surge of interest in the field focusing on clinical development of IN inhibitors. Here, we summarise the current status of IN inhibitors under clinical development. These agents include S-1360, GSK-364735, L-870,810, L-870,812, MK-0518, GS-9137, L-900564, GS-9224, and BMS-707035. Promising antiviral activity has already been achieved with MK-0518 and GS-9137 in late-stage clinical studies. © 2007 Adis Data Information BV. All rights reserved.

引用

页码：155 / 168

页数：13

共 50 条

[1]

Chun T.W., Finzi D., Margolick J., Et al., In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency, Nat Med, 1, 12, pp. 1284-1290, (1995)

[2]

Saksena N.K., Potter S.J., Reservoirs of HIV-1 in vivo: Implications for antiretroviral therapy, AIDS Rev, 5, 1, pp. 3-18, (2003)

[3]

Potter S.J., Dwyer D.E., Saksena N.K., Differential cellular distribution of HIV-1 drug resistance in vivo: Evidence for infection of CD8+ T cells during HAART, Virology, 305, 2, pp. 339-352, (2003)

[4]

Potter S.J., Lemey P., Dyer W.B., Et al., Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART, Virology, 348, 1, pp. 35-46, (2006)

[5]

Wainberg M.A., Sawyer J.P., Montaner J.S., Et al., Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection, Antivir Ther, 10, 1, pp. 13-28, (2005)

[6]

Yusa K., Harada S., Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro, Curr Pharm Des, 10, 32, pp. 4055-4064, (2004)

[7]

Shet A., Berry L., Mohri H., Et al., Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience, J Acquir Immune Defic Syndr, 41, 4, pp. 439-446, (2006)

[8]

Shet A., Markowitz M., Transmitted multidrug resistant HIV-1: New and investigational therapeutic approaches, Curr Opin Investig Drugs, 7, 8, pp. 709-720, (2006)

[9]

Bushman F.D., Craigie R., Activities of human immuno-deficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA, Proc Natl Acad Sci U S A, 88, 4, pp. 1339-1343, (1991)

[10]

Neamati N., Patented small molecule inhibitors of HIV-1 integrase: A 10-year saga, Expert Opin Ther Pat, 12, 5, pp. 709-724, (2002)

← 1 2 3 4 5 →